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[Abstract] 
In the synthesis of radiometal-labeled probes, a large excess of ligands over radiometals are 
required to provide radiometal-labeled probes with high radiochemical yield in short reaction time. 
However, the unlabeled ligands hinder target accumulation of the radiometal-labeled probes by 
competing for target molecules. To circumvent the problem, our laboratory has developed a new 
design concept of “metal coordination-mediated synthesis” 99mTc-labeled bivalent and trivalent 
probes. The 99mTc-labeled probes acquire higher binding affinities upon complexation with 
monovalent ligand by multivalent effect, and the resulting probes visualized the target molecule 
by SPECT/CT without removing the unlabeled ligand. 68Ga is a positron emitter available from a 
long-lived 68Ge/68Ga generator system, which allows for the cost-effective production of PET 
probes without cyclotron facilities. The study was undertaken to develop the chemical strategy to 
apply the molecular design achieved with 99mTc-labeled probes to 68Ga-labeled ones. Since 67Ga- 
and 68Ga-labeled probes were obtained under similar reaction conditions, 67Ga was used in this 
study as a radionuclide of choice because of its longer half-life and availability. 
Chapter 1 Chemical strategy to apply the chemical design developed with 99mTc-labeled 
probes to 68Ga-labeled ones.  
Based on the procedures of 99mTc-labeled bivalent and trivalent probes, 3-hydroxy-1,2-dimethyl-
4-pyridone (Hdpp) and 2-acetylpyridine N,N-disubstituted thiosemicarbazone (PTSC) derivatives 
were selected as a bidentate and a tridentate chelator, due to a formation of thermodynamically 
stable complexes with the Ga3+ ion. Hdpp provided a single radioactive peak on TLC at an Rf 
value identical to that of non-radioactive Ga-(Hdpp)3 complex verified by ESI-MS when the 
developing solution contained 10 mM Hdpp. On RP-HPLC analysis of the reaction mixture, the 
majority of the radioactivity was adsorbed on the column. These results indicated that while Hdpp 
may provide [67Ga]Ga-(Hdpp)3, the complex underwent rapid decomposition under low Hdpp 
concentrations, which was not appropriate for in vivo applications. PTSC derivatives also provided 
the objective [67Ga]Ga-(PTSC)2 complexes. The 67Ga-labeled complexes remained stable after 
removing the unlabeled free ligand by RP-HPLC. However, the RP-HPLC-purified [67Ga]Ga-
(PTSC)2 derivatives were rapidly decomposed when incubated in 0.1 M bicarbonate buffer (pH 
7.4) at 37 ºC. These results indicated that while the tridentate chelates increased the stability of the 
resulting 67Ga complexes, their stability was insufficient for in vivo applications. These results 
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called for an alternative approach to prepare multivalent 67Ga-labeled probes from monovalent 
ligands. Free Schiff base chelators are present as equilibrium and are rapidly decomposed upon 
dilution. However, the Schiff base remains stable through metal coordination. From these 
considerations, a Schiff base chelator was designed and synthesized by reacting salicylaldehyde 
(Sal) with triamine compound TAMEol to prepare (Sal)3TAMEol. [67Ga]Ga-(Sal)3TAMEol was 
prepared by adding [67Ga]Ga-citrate to a solution of (Sal)3TAMEol at 80 ˚C for 15 min. [67Ga]Ga-
(Sal)3TAMEol remained stable after isolation from the excess of Sal and TAMEol. Furthermore, 
[67Ga]Ga-(Sal)3TAMEol was stable in the apo-transferrin challenge. As a result, [67Ga]Ga-
(Sal)3TAMEol provided 67Ga-complex possessing kinetic stability worth for further evaluation. 
Chapter 2. Evaluation of the Schiff base ligand for in situ trivalent “1 to 3” design.  
The reaction of [67Ga]Ga-citrate with a mixture of RGD-conjugated salicylaldehyde and triamine 
provided a 67Ga-labeled trivalent probe [67Ga]Ga-(RGD-Sal)3TAMEol with stability sufficient for 
in vivo applications. The unlabeled ligands exhibited the much less inhibitory effect on the 
[67Ga]Ga-(RGD-Sal)3TAMEol accumulation to the target molecules compared with a 67Ga-labeled 
probe  prepared under the conventional “3 to 3” approach, due to rapid decomposition of (RGD-
Sal)3TAMEol to RGD-Sal and TAMEol after injection. As a result, [67Ga]Ga-(RGDsal)3TAMEol 
visualized murine tumors without post-labeling purification, more clearly than that of 67Ga-labeled 
trivalent probe from a trivalent ligand.  
Conclusion.  
Since the procedure achieved with 99mTc-labeled probes was not applicable to prepare 67Ga-labeled 
probes, an alternative approach was developed utilizing Schiff base-stabilization upon metal 
coordination. This approach generated a 67Ga-labeled trivalent probe of high in vivo stability and 
the resulting 67Ga-labeled probe provided clear tumor images without post-labeling purification. 
These findings indicate the availability of Schiff base ligands to prepare 68Ga-labeled trivalent 
probes by a simple radiolabeling procedure. The present findings would facilitate the applications 
of 68Ga-labeled probes in molecular imaging with PET. 
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[Background] 
Radiolabeled probes are radionuclide-containing pharmaceuticals and are used routinely in 
nuclear medicine for diagnosis or therapy of diseases. The radiolabeled diagnostic probe is a 
molecule labeled with a γ-emitting radionuclide for single photon emission computed tomography 
(SPECT) or with a positron-emitting radionuclide for positron emission tomography (PET).1–3 
SPECT and PET are molecular imaging modalities and are powerful clinical and research tools for 
diagnosis, staging treatment planning, and therapeutic efficacy monitoring of patients. SPECT 
requires the use of an imaging probe labeled with a γ-emitting radionuclide. These γ rays are 
recorded by the detectors with a collimator to arrange the direction from multiple angles. SPECT 
instrument can be converted into the 3-D image identifying the localization of the radiotracer. The 
radionuclides used for SPECT is commercially available and used in SPECT imaging facility. 
Therefore, SPECT is more available and widely used and much cheaper than PET. On the other 
hand, PET is the molecular imaging instrument that requires a positron-emitting radionuclide 
labeled probe. The anti-parallel 511 keV γ rays emitted from the annihilation of positrons with 
surrounding electrons are recorded by detectors arranged in a ring around the subject. The data are 
then reconstructed using computer-based algorithms to yield the 3-D image of the radiotracer’s 
location. Compared with SPECT, PET has greater advantages regarding sensitivity and resolution 
since only two photons detected in coincidence are registered, eliminating unnecessary physical 
collimation to block scattered photons.4 However, due to the short half-lives of the PET 
radioisotopes such as carbon-11 (20 min), nitrogen-13 (10 min), oxygen-15 (2 min) and fluorine-
18 (110 min), the radiolabeled probes labeled by these radionuclides have traditionally been 
produced using an in-house cyclotron of the PET imaging facility. 
Recently, Germanium-68 (68Ge)/Gallium-68 (68Ga) generators became commercially available 
and are used in the clinical stages.5 The relation of 68Ge decay and 68Ga accumulation is described 
by secular equilibrium since the half-life of the 68Ge (t1/2 = 271 d) is over 100 times longer than 
that of 68Ga (t1/2 = 67.7 min). At the equilibrium, the daughter radionuclide (68Ga) reaches the 
radioactivity identical to that of the parental radionuclide (68Ge). In addition, 4 h after the elution 
of the daughter radionuclide, 91% of the maximum achievable radioactivity is generated, which 
allows the synthesis of 68Ga-labeled probes twice or three times within one working day. The 
availability of 68Ga from a generator system also allows for the cost-effective production and the 
use of 68Ga-labeled probes for PET imaging without an in-house cyclotron facility.6 Another 
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advantage of radiometals such as 68Ga over non-metallic radionuclides (e.g., 11C and 18F) involves 
the synthesis of the objective radiolabeled probes in radiochemical yields sufficient for 
administration to subjects without purification.3,7,8 These characteristics make 68Ga as an attractive 
radionuclide for preparing PET imaging probes. Gallium possesses another radioisotope, 67Ga (t1/2 
= 78.3 h), that emits γ-rays available from a commercial source. Since 67Ga and 68Ga-labeled 
probes are prepared under similar reaction conditions,9–11 the results obtained from 67Ga-labeled 
probes can be applied to 68Ga-labeled probes and vice versa. Thus, the use of 67Ga compensates 
the short half-life of 68Ga for developing 68Ga-labeled probes. 
In the design of 68Ga-labeled probes, low molecular weight biomolecules such as peptides are 
used as a targeting device to deliver 68Ga to the target molecules. Since most bioactive molecules 
do not form stable complexes with metallic radionuclides such as 67/68Ga, technetium-99m (99mTc) 
and indium-111, a chelating agent is conjugated to a biomolecule (referred to as “ligand”)4,12–14 to 
provide a coordination site for the radiometals. The subsequent complexation reaction of the 
chelating agent-conjugated biomolecule with a metallic radionuclide provides a radiolabeled probe. 
A schematic illustration of a targeted radiometal-labeled probe is shown in Figure 1.  
To ensure high radiochemical yields in short reaction time using extremely low concentration of 
radiometals (e.g. 68Ga: 37 MBq/mL corresponding to 4 × 10-10 M, 67Ga: 2.5 × 10-8 M)12 with the 
ligand, the radiolabeled ligands are synthesized in the presence of a large excess of ligands over 
radiometals (Figure 2). The presence of a large excess of unlabeled ligands in the injectate impairs 
target uptake of the radiolabeled ligands by competing for target molecules, which results in poor 
images of the target molecules of low expression levels.7,15–18 68Ga-labeled probes so far developed 
need the removal of the non-chelated free ligand by HPLC or other purification methods. However, 
such manipulation significantly wastes time and radioactivity and impairs the practical utility and 
advantages of using radiometals, especially for 68Ga due to the short half-life. In other words, the 
applications of 68Ga-labeled probes would increase significantly if 68Ga-labeled probes can be 
obtained without post-labeling purification.  
To ensure high radiochemical yields in short reaction time, due to the low concentration of 
radiometals (e.g. 68Ga: 37 MBq/mL corresponding to 4 × 10-10 M, 67Ga: 2.5 × 10-8 M),12 the 
radiolabeled ligands are then synthesized in the presence of a large excess of ligands over 
radiometals (Figure 2). The presence of a large excess of unlabeled ligands in the injectate impairs 
target uptake of the radiolabeled ligands by competing for target molecules, which results in poor 
 
Figure 1. A schematic illustration of radiometal-labeled probe. A biomolecule is conjugated 
with a bifunctional chelator to produce a biomolecule chelator probe which called ligand. The 
complexation reaction of a radiometal and a ligand provides a radiolabeled probe with 
stability sufficient for in vivo studies.  
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images of the target molecules of low expression levels.7,15–18 Although the free ligands can be 
removed from the radiolabeled-ligands by HPLC or other purification methods, such manipulation 
significantly wastes time and radioactivity and impairs the practical utility and advantages of the 
use of radiometals, especially for 68Ga due to the short half-life. 
 
To circumvent the problem, our laboratory has recently developed a new design concept of 
“metal coordination-mediated synthesis” 99mTc-labeled trivalent probes using 
[99mTc][Tc(CO)3(OH2)3]+ and isonitrile-conjugated Arg-Gly-Asp (RGD) peptide (CN-RGD).17 In 
this design, three water molecules in [99mTc][Tc(CO)3(OH2)3]+ are displaced with the three 
monovalent ligands (CN-RGD) to prepare a trivalent [99mTc][Tc(CO)3(CN-RGD)3]+ probe. As a 
result, [99mTc][Tc(CO)3(CN-RGD)3]+ acquired higher integrin αvβ3 binding affinity than its 
monovalent ligand (Figure 3A-1). When injected into mice, [99mTc][Tc(CO)3(CN-RGD)3]+ 
showed higher tumor uptake and higher tumor to blood ratio. In SPECT imaging studies, 
[99mTc][Tc(CO)3(CN-RGD)3]+ clearly visualized murine tumors without removing the unlabeled 
ligands. In contrast, a 99mTc-labeled monovalent probe prepared from a monovalent ligand failed 
to depict the tumors in the presence of the unlabeled ligands. Our laboratory has also reported the 
applicability of this design concept to 99mTc-labeled bivalent probes using D-penicillamine as a 
 
Figure 2. A conceptual illustration of the conventional design synthesis of radiometal-labeled 
probes. (A) Monovalent “1 to 1” design, (B) Trivalent “3 to 3” design. The presence of excess 
unlabeled ligands with similar affinity hinders target accumulation of the radiometal-labeled 
probes by competing for target molecules. 
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chelating molecule (Figure 3A-2).18 Based on the results of these studies, I investigated an 
appropriate procedure to apply the chemical design developed with 99mTc-labeled probes to 68Ga-
labeled ones. I conducted the present studies with 67Ga because of its longer half-life and 
availability. 
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Figure 3. A conceptual illustration of the in situ molecular design of multivalent probes. (A) In 
situ trivalent “1 to 3” design (A-1) and “1 to 2” divalent design (A-2). The radiolabeled probes 
prepared from the monovalent ligand acquired higher binding affinity than the monovalent 
ligand upon complexation by so-called multivalent effect. (B) Modified in situ “1 to 3” design. 
The radiolabeled probe was synthesized by reacting a radiometal ion with a trivalent Schiff base 
hexadentate ligand prepared from a monovalent ligand with an aldehyde group and a triamine 
molecule at the molar ratio of 3:1. While the Schiff base is stabilized upon metal coordination, 
the unlabeled Schiff base ligands present as equilibrium in the injectate are decomposed 
immediately after injection. As a result, the metal complex is an only trivalent compound and 
possess higher binding affinity than its unlabeled monovalent ligand. 
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[Chapter 1]. Chemical strategy to apply the chemical design developed with 99mTc-labeled 
probes to 67/68Ga-labeled ones. 
1-1. Bidentate or tridentate chelators based on the procedures applied to 99mTc 
[Introduction] 
Based on the procedures applied to 99mTc-labeled probes, bidentate or tridentate chelators were 
used to investigate the applicability of the molecular design of the “metal coordination-mediated 
synthesis” of 67Ga-labeled multivalent probes. The hydroxypyridinone derivatives consist of a six-
membered aromatic N-heterocycle with a hydroxyl and a ketone functionality. At physiological 
conditions, they present the high affinity for hard trivalent metal ions such as Iron-(III) (Fe3+) and 
the group 13 metal ions particularly for Ga,19,20 and provide a thermodynamically stable complex 
with the Ga3+ ion.19,21,22 From these studies, I selected 3-hydroxy-1,2-dimethyl-4-pyridone (Hdpp) 
as the bidentate chelator (Figure 4A).19,21 
As for the tridentate chelators, 2-acetylpyridine N,N-disubstituted thiosemicarbazone (PTSC) 
derivatives were selected (Figure 4B).23,24 Thiosemicarbazones have been extensively studied as 
toxic agents against bacterial and viral infections. Non-radioactive Ga complexes of 
thiosemicarbazone were also evaluated as ribonucleotide reductase inhibitors.25 The 4N-
substituted α-N-heterocyclic thiosemicarbazone forms thermodynamically stable complex with Ga 
and the complex exhibits a potent antiproliferative action.25 Therefore, the applicability of these 
approaches was investigated.  
 -10-  
 
[Results] 
(1-1.1) Synthesis of non-radioactive Ga-(Hdpp)3.  
To a suspension of 3-Hydroxy-1,2-dimethyl-4-pyridone (Hdpp) in water (5 mL) was added a 
solution of GaCl3 in water. After adjusting the pH of the solution to 9 with 2 N NaOH, the reaction 
mixture was heated at 70 ˚C until the reaction volume was <2.5 mL. After cooling to room 
temperature, the precipitate was collected by filtration and Ga-(Hdpp)3 was obtained as an orange 
solid (20.6 mg, 58%).  
(1-1.2) Preparation of [67Ga]Ga-(Hdpp)3.  
A solution of Hdpp in 0.1 M acetate buffer was reacted with [67Ga]Ga-citrate at 80 ˚C for 30 
min. The major radioactivity was observed at the origin in cellulose acetate electrophoresis (CAE) 
analysis (Figure 5B). Under these conditions, [67Ga]Ga-citrate migrated 4 cm towards the anode 
(Figure 5A), suggesting a formation of a 67Ga-labeled Hdpp. A broad radioactivity peak from the 
Rf values of 0 to 0.2 was observed in TLC analysis (Figure 5C). When Hdpp (10 mM) was added 
 
Figure 4. In situ multivalent designs based on the design applied to 99mTc-labeled probes. (A) 
In situ trivalent “1 to 3” design using bidentate Hdpp chelator. (B) In situ bivalent “1 to 2” 
design using tridentate PTSC derivatives chelators. Reactions with 67Ga provided its 67Ga-
complexes. 
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to the developing solvent, a sharp radioactivity peak was observed at the Rf value of 0.3 (Figure 
5D) similar to that of non-radioactive Ga-(Hdpp)3 characterized and verified by ESI-MS. 
 
  
 
Figure 5. Analysis of [67Ga]Ga-(Hdpp)3. CAE radioactivity traces of (A) [67Ga]Ga-(Hdpp)3 and 
(B) [67Ga]Ga-citrate. TLC radioactivity traces of [67Ga]Ga-(Hdpp)3 developed with 
MeOH/water (C) without and (D) with 10 mM Hdpp. 
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(1-1.3) Synthesis of tridentate PTSC derivatives.  
The PTSC derivatives were synthesized by reacting 2-acetylpyridine with S-methyl 
dithiocarbazate26 in ethanol at 80 ºC, followed by the alkylation with secondary amines, as shown 
in Scheme 1.  
 
 
(1-1.4) Synthesis of non-radioactive Ga-(PTSC-1)2 and Ga-(PTSC-2)2. 
A mixed solution of Ga(NO3)3/nH2O and PTSC-1 or PTSC-2 in EtOH was reacted at 40 ˚C for 
1 h. A solution of ammonium hexafluorophosphate in EtOH was added to the solution. After 
mixing for 10 min, the precipitates were obtained by filtration to afford Ga-(PTSC-1)2 or Ga-
(PTSC-2)2.  
(1-1.5) Preparation of [67Ga]Ga-(PTSC)2. 
[67Ga]GaCl3 was mixed with 0.1 M ammonium acetate, and the reaction mixture was left for 5 
min. This solution was then mixed with PTSC derivatives in a mixture of EtOH and 0.1 M 
ammonium acetate pH 4.5 (1:8), and the reaction mixture was heated at 80 ˚C for 15 min. The RP-
HPLC analyses of the reaction solution showed a single radioactivity peak at a retention time 
Scheme 1. Synthesis of PTSC derivatives 
 
Reagents : (a) bis(2-methoxyethyl)amine, (b) diisobutylamine. 
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similar to those of the corresponding non-radioactive Ga-(PTSC)2 derivatives verified by ESI-MS 
(Figure 6).  
 
  
 
Figure 6. RP-HPLC UV (254 nm) traces of Ga-(PTSC-1)2 (A) and Ga-(PTSC-2)2 (B) 
and radioactivity traces of [67Ga]Ga-(PTSC-1)2 (C) and [67Ga]Ga-(PTSC-2)2 (D). 
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(1-1.6) Stability of [67Ga]Ga-(PTSC)2 derivatives.  
67Ga-labeled complexes were purified by RP-HPLC to remove unlabeled ligands. The 
radioactive peak was collected and the solvent was removed in vacuo. The residue was 
reconstituted in carbonate buffer (0.1 M, pH 7.4). Aliquots of the samples were collected after 1, 
3 and 6 h incubation, and the radioactivity was analyzed by TLC (ammonium acetate : MeOH/1 : 
1). [67Ga]Ga-(PTSC)2 derivatives were rapidly decomposed after 1 h incubation at 37 ˚C (Table 
1). 
 
[Discussion] 
When Hdpp was reacted with [67Ga]Ga-citrate at 80 ˚C for 30 min, a broad radioactivity peak 
from the Rf values of 0 to 0.2 was observed in TLC analysis (Figure 5C). However, a sharp 
radioactivity peak was observed at an Rf value of 0.3 similar to that of non-radioactive Ga-(Hdpp)3 
characterized and verified by ESI-MS when Hdpp (10 mM) was added to the developing solvent. 
On RP-HPLC analysis, the majority of the radioactivity was adsorbed on the column and was not 
eluted (data not shown). These results indicated that while Hdpp may provide an objective 
[67Ga]Ga-(Hdpp)3 complex, the complex underwent rapid decomposition under low Hdpp 
concentration, indicating that [67Ga]Ga-(Hdpp)3 complex is not kinetically stable and is not 
appropriate for in vivo applications. 
Contrary to [67Ga]Ga-(Hdpp)3, both [67Ga]Ga-(PTSC-1)2 and [67Ga]Ga-(PTSC-2)2 remained 
stable after isolation from the free ligands as observed in the RP-HPLC analyses. However, both 
[67Ga]Ga-(PTSC)2 were rapidly decomposed after incubation in 0.1 M bicarbonate buffer (pH 7.4) 
Table 1. Stability of [67Ga]Ga-(PTSC-1)2 and [67Ga]Ga-(PTSC-2)2 in 0.1 M bicarbonate 
buffer (pH 7.4)a 
 percent of intact radiolabeled complex (%) 
time (min) [67Ga]Ga-(PTSC-1)2 [67Ga]Ga-(PTSC-2)2 
10 70.4 ± 9.67 31.0 ± 3.24 
30 47.1 ± 4.83 5.60 ± 0.38 
60 5.73 ± 1.55 0.71 ± 0.32 
aExpressed as mean ± s.d. for three experiments. 
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at 37 ºC (Table 1). These results indicated that while the tridentate ligands increased the stability 
of the resulting 67Ga complexes than that from the bidentate ligands, their stability was insufficient 
for in vivo applications. These results called for an alternative approach to prepare multivalent 
67Ga-labeled probes from monovalent ligands. These results also suggested that a hexadentate 
chelator would be appropriate to prepare kinetically inert Ga complexes.27–29 
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1-2. Schiff base chelator 
[Introduction]  
The results of a bidentate or a tridentate chelator suggested the use of hexadentate chelator to 
prepare 67/68Ga-labeled probes of high stability. To reduce the competitive inhibition of the free 
ligand, the non-coordinated free chelator should be decomposed upon injection to subjects. To 
satisfy the criterion, a Schiff base chelator was selected as the next candidate.30 Schiff bases (also 
known as an imine or azomethine) are condensation products of primary amines with carbonyl 
compounds such as aldehydes or a ketones. Free Schiff base chelators are present as equilibrium 
in the aqueous solution and are rapidly decomposed upon dilution while the Schiff base remains 
stable through metal coordination (Figure 3B)31 as well exemplified by 99mTc-labeled pyridoxal 
isoleucine for hepatobiliary tract imaging.32,33 From these considerations, a Schiff base chelator 
was designed and synthesized by reacting a salicylaldehyde (Sal) with a triamine compound, 
2,2’,2”-tri(aminomethyl)ethanol (TAMEol), to prepare (Sal)3TAMEol (Figure 7). The 
applicability of this approach was investigated.  
 
Figure 7. Modified in situ trivalent “1 to 3” design using hexadentate Schiff base 
(Sal)3TAMEol with 67Ga. The Schiff base ligand (Sal)3TAMEol is stabilized upon 67Ga 
coordination, while the free Schiff base ligand is decomposed to Sal and TAMEol after the 
change in the equilibrium state such as dilution. 
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[Results] 
 
(1-2.1) Synthesis of Schiff base ligand (Sal)3TAMEol and the Ga-complex.  
The Schiff base chelator was synthesized by reacting a Sal with a triamine compound TAMEol 
in MeOH (scheme 2) with 27% yield. The Ga-complex was prepared by refluxing the mixture of 
(Sal)3TAMEol and Ga-complex of acetylacetonate in ethanol solution with 54% yield. 
Scheme 2. Synthesis of (Sal)3TAMEol 
 
Reagents and conditions : (a) NaN3, DMF; (b) Pd/C, H2, MeOH; (c) Boc2O, NaHCO3, 
MeCN; (d) HCl/ AcOEt; (e) Salycilaldehyde, MeOH. 
 
Figure 8. Analysis of (Sal)3TAMEol dissolved in ethanol solution (A) or phosphate buffer 
solution (B) by RP-HPLC. 
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(1-2.2) Evaluation of stability of (Sal)3TAMEol in aqueous solution.  
(Sal)3TAMEol dissolved in a mixed solution of EtOH solution and phosphate buffer was 
incubated at 37 ˚C for 1 h. RP-HPLC analyses revealed that while (Sal)3TAMEol was present in 
the EtOH solution (Figure 8A), (Sal)3TAMEol was decomposed to Sal and TAMEol in the 
phosphate buffer (Figure 8B). 
 
(1-2.3) Preparation of [67Ga]Ga-(Sal)3TAMEol.  
[67Ga]Ga-(Sal)3TAMEol was prepared in 95% radiochemical yield by reacting the EtOH 
solution of (Sal)3TAMEol with [67Ga]Ga-citrate, followed by heating the reaction mixture at 80 
˚C for 15 min (Figure 9A). The RP-HPLC retention time of the [67Ga]Ga-(Sal)3TAMEol was 
similar to that of the corresponding non-radioactive Ga-complex characterized by ESI-MS (Figure 
9B). 
 
  
 
Figure 9. RP-HPLC radioactivity profile of [67Ga]Ga-(Sal)3TAMEol (A) and 
69Ga-ion count profile of Ga-(Sal)3TAMEol (B). 
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The RP-HPLC analysis of [67Ga]Ga-(Sal)3TAMEol by UV trace showed two peaks 
corresponding to Sal and benzyl alcohol, a preservative in [67Ga]Ga-citrate, and the intact of 
(Sal)3TAMEol was not observed (Figure 10). 
  
 
Figure 10. RP-HPLC analyses of the labeling solution of [67Ga]Ga-(Sal)3TAMEol 
by UV (A) and radioactivity (B). 
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(1-2.4) Stability study of [67Ga]Ga-(Sal)3TAMEol.  
The stability of [67Ga]Ga-(Sal)3TAMEol was evaluated in an apo-transferrin solution at 37 ˚C 
for 6 h (Table 2). [67Ga]Ga-(Sal)3TAMEol remained stable against the apo-transferrin challenge. 
After 6 h incubation, over 95% of the radioactivity remained intact. 
 
[Discussion] 
Schiff base is present as an equilibrium of an amine and an aldehyde in aqueous solution. The 
hydrolysis of Schiff base begins with the binding of water molecules to carbon to form 
carbinolamine intermediate. If an unshared electron pair on the nitrogen atom of the Schiff base is 
used for coordination with a metal, the carbinolamine intermediate is not formed, and the Schiff 
base remains intact in an aqueous solution.34,35 Therefore, a hexadentate ligand, (Sal)3TAMEol, 
prepared from TAMEol and three molecules of a bidentate ligand Sal, was designed and 
synthesized.  
The synthesis of [67Ga]Ga-(Sal)3TAMEol was conducted by mixing an ethanolic solution of 
(Sal)3TAMEol with [67Ga]Ga-citrate. To confirm the structure of the 67Ga-labeled compound, non-
radioactive Ga-(Sal)3TAMEol was synthesized and characterized by ESI-MS. Although I did not 
analyze the compound by X-ray crystallography, the previous report indicated that the Ga-complex 
is formed by hexadentate N3O3 coordination.36 As mentioned above, Schiff base constitutes a 
useful coordination molecule not only for Ga but for 99mTc as well.32,33 First, I evaluated the 
retention time of non-radioactive Ga-(Sal)3TAMEol by RP-HPLC with UV. Since the solubility 
of the non-radioactive Ga-(Sal)3TAMEol was too low to be detectable by the UV detector, ICP-
MS was used to determine the retention time of Ga-(Sal)3TAMEol (Figure 9B). The RP-HPLC 
Table 2. Stability of [67Ga]Ga-(Sal)3TAMEol in apo-transferrin solutiona  
Time (h) Percent of intact radiolabeled complex (%) 
1 97.0 ± 0.7 
3 96.6 ± 0.6 
6 95.3 ± 0. 7 
aExpressed as mean ± s.d. for three experiments. 
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analysis of [67Ga]Ga-(Sal)3TAMEol showed a retention time similar to that of the corresponding 
non-radioactive Ga-complex analyzed by ICP-MS (Figure 9). These results indicated that 
[67Ga]Ga-(Sal)3TAMEol was obtained with a radiochemical yield of over 95% at a ligand 
concentration of 1 mM. When the labeling solution was analyzed by RP-HPLC with UV, Sal was 
mainly observed and the free (Sal)3TAMEol was not observed (Figure 10). These phenomena 
indicated that the free Schiff base (Sal)3TAMEol was decomposed during the HPLC analysis and 
[67Ga]Ga-(Sal)3TAMEol was present as the only trivalent compound due to the stabilization of the 
Schiff base by Ga-coordination. Since the administration of the 67Ga-labeled solution to subjects 
forwards the equilibrium of the free Schiff base to dissociation, [67Ga]Ga-(Sal)3TAMEol would 
become the sole trivalent compound in the body. These results supported the hypothesis that the 
use of the metal-stabilized property of the Schiff base ligand would provide an alternative way to 
prepare 67/68Ga-labeled trivalent probes from monovalent ligands, as demonstrated with 
[99mTc]Tc[(CO)3(CN-RGD)3]+ trivalent probe from the monovalent isonitrile-conjugated RGD.17 
Another important issue to be evaluated is the plasma stability of the [67Ga]Ga-(Sal)3TAMEol, 
since an iron-binding protein, apo-transferrin, is a strong chelator for Ga present in the plasma. 
[67Ga]Ga-(Sal)3TAMEol remained stable during RP-HPLC analysis and after isolation from the 
excess of Sal and TAMEol. Furthermore, [67Ga]Ga-(Sal)3TAMEol remained stable after 
incubation with apo-transferrin (Table 2). These results confirmed that the 67Ga-complex has 
stability sufficient for further evaluation. 
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[Summary]  
[67Ga]Ga-(Hdpp)3 complex synthesized from a bidentate ligand, Hdpp, could not be isolated 
due to rapid decomposition during isolation process, while the [67Ga]Ga-(PTSC)2 complexes from 
tridentate ligands remained stable after isolation from the free ligands. However, the [67Ga]Ga-
(PTSC)2 complexes suffered from decomposition in bicarbonate buffer which called for further 
modifications of PTSC structure to develop a chelator that forms a kinetically inert 67Ga-complex 
for in vivo applications. Contrary to the bidentate and tridentate ligand, [67Ga]Ga-(Sal)3TAMEol 
remained stable after 6 h incubation in apo-transferrin solution while the free (Sal)3TAMEol 
exhibited rapid decomposition during the HPLC analysis. These results indicated that [67Ga]Ga-
(Sal)3TAMEol synthesized from the Schiff base compound provided 67Ga-complex of high kinetic 
stability worth for further evaluation. 
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Chapter 2. To evaluate the applicability of the new design towards 67Ga after conjugation 
with a cyclic RGDfK (-Arg-Gly-Asp-D-Phe-Lys-: c(RGDfK)) peptide. 
[Introduction] 
As mentioned in the Chapter 1, a Schiff base ligand, [67Ga]Ga-(Sal)3TAMEol, provided a 67Ga-
labeled trivalent probe with stability sufficient for in vivo studies. The free Schiff base ligand 
present in the solution was decomposed rapidly into the monovalent Sal and TAMEol upon 
dilution. These results suggested that the present molecular design would constitute an alternative 
procedure to achieve the concept of the coordination-mediated multivalency. To further evaluate 
the molecular design, a cyclic RGDfK peptide (Arg-Gly-Asp-D-Phe-Lys) was selected as a 
targeting molecule, and a 67Ga-labeled trivalent c(RGDfK) probe was synthesized. The c(RGDfK) 
peptide is a specific antagonist for the integrin αvβ3 that overexpressed on activated endothelial 
cells during physiological and pathological angiogenesis and tumor cells.37 Moreover, this 
targeting moiety was used in the previous studies to evaluate the coordination-mediated 
multivalent concept with 99mTc-labeled compounds.17,18 Thus, 67Ga-labeled Schiff base conjugated 
with c(RGDfK)-peptides via aminohexanoic acid as a spacer was designed and synthesized 
([67Ga]Ga-(RGD-Sal)3TAMEol) (Figure 11A). The stability, integrin αvβ3 binding affinity and 
biodistribution studies in U87MG human glioma bearing nude mice was evaluated. A 67Ga-labeled 
1,4,7-triazacyclononane-1,4,7-tris-(glutaric acid) (NOTGA) conjugated c(RGDfK) ([67Ga]Ga-
NOTGA(RGD)3) was synthesized and used as a reference of the conventional “3 to 3” approach 
(Figure 11B). 
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Figure 11. (A) In situ trivalent “1 to 3” Schiff base conjugated RGD peptide. Sal is 
conjugated with cRGDfK to prepare monovalent RGD-Sal, subsequent reaction with 
TAMEol and Ga provides trivalent Ga-(RGD-Sal)3TAMEol (B) Reference trivalent 
compound prepared by conventional multivalent “3 to 3” design.  
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[Results] 
(2.1) Synthesis of c[Arg(Pbf)-Gly-Asp(tBu)-D-Phe-Lys] 
The synthesis of c[Arg(Pbf)-Gly-Asp(tBu)-D-Phe-Lys] was performed based on the previous 
report.38 After Fmoc solid-phase peptide synthesis and cyclization in the liquid phase, protected-
c(RGDfK) peptide, c[Arg(Pbf)-Gly-Asp(tBu)-D-Phe-Lys], was obtained in 80% yields (Scheme 
3). 
  
Scheme 3. Synthesis of c[R(Pbf)GD(tBu)fK 
 
Trt(2Cl)Resin-Gly-NH2
(a) Fmoc-Arg(Pbf)-OH, (i), (ii) ; (b) Fmoc-Lys(Z)-OH, (i), (ii) (c) Fmoc-D-Phe-OH, (i), (ii); 
(d) Fmoc-Asp(tBu)-OH, (i), (ii); (e) CH3COOH, TFE, CH2Cl2; 
(f) DPPA, NaHCO3, DMF; (g) Pd/C, DMAC
(i) DIC, HOBt, DMF
(ii) 20% piperidine/DMF
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(2.1) Synthesis of RGD-conjugated Sal.  
The synthetic procedure for RGD-Sal is illustrated in Scheme 4. Fmoc-protected aminohexanoic 
acid was activated to an active ester and then conjugated with the protected cRGDfK peptide. The 
resulting aminohexanoic acid-conjugated RGD was then conjugated with the aldehyde protected 
o-amino-phenol 10 to prepare compound 15. RGD-Sal (16) was obtained after removing the 
protecting groups and subsequent RP-HPLC purification (Figure 12). 
 
  
Scheme 4. Synthesis of RGD-conjugated Sal. 
 
 
Reagents : (a) Fmoc-OSu, (b) TFP, DCC, (c) c(R(Pbf)GD(tBu)fK) (d) 20% piperidine/DMF, (e) 
TFA, hexamethylenetetramine, (f) o-aminophenol (g) DCC, HOAt, (h) TFA/water 9:1. 
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Figure 12. RP-HPLC analysis of RGD-Sal (system 2). The purity of RGD-Sal was 98.3%. 
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(2.2) Preparation of non-radioactive Ga-(RGD-Sal)3TAMEol. 
A mixture of RGD-Sal, TAMEol in ammonium acetate was reacted with GaCl3 at pH 8 for 8 h 
at 70 ˚C. The compound was purified by a preparative RP-HPLC to obtain the compound in 83% 
yields.  
 
(2.3) Preparation of [67Ga]Ga-(RGD-Sal)3TAMEol.  
[67Ga]Ga-(RGD-Sal)3TAMEol was prepared in 95% radiochemical yields by heating a mixed 
solution of RGD-Sal, TAMEol and [67Ga]Ga-citrate at 70 ºC for 1 h. The final concentration of 
RGD-Sal was 2.5 × 10-4 M.  
The RP-HPLC analysis of [67Ga]Ga-(RGD-Sal)3TAMEol showed a single radioactive peak at 
a retention time similar to that of the non-radioactive Ga-(RGD-Sal)3TAMEol characterized and 
verified by ESI-MS (Figure 13).  
 
Figure 13. RP-HPLC profiles of [67Ga]Ga-(RGD-Sal)3TAMEol. (A) Non-radioactive Ga-
(RDG-Sal)3TAMEol verified by ESI-MS, (B) the radiotrace of [67Ga]Ga-(RGD-Sal)3TAMEol 
and (C) the UV (254 nm) trace of the same sample. A single radioactivity peak was observed 
at a retention time similar to that of non-radioactive Ga-(RDG-Sal)3TAMEol. The UV trace 
showed two peaks, corresponding to RGD-Sal and benzyl alcohol (BnOH). 
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 (2.4) Preparation of [67Ga]Ga-NOTGA(RGD)3.  
[67Ga]Ga-NOTGA(RGD)3 was synthesized by the conventional method using 
NOTGA(RGD)3 at pH 5, and the reaction proceeded in 20 min at room temperature. Under these 
conditions, [67Ga]Ga-NOTGA(RGD)3 was obtained over 95% radiochemical yields. The RP-
HPLC retention time of 67Ga-complex was identical to the corresponding non-radioactive Ga-
complex characterized and verified by ESI-MS separately (Figure 14). 
 
  
 
Figure 14. RP-HPLC UV-chromatogram of Ga-NOTGA(RGD)3 (A) and radio-chromatograms 
of [67Ga]Ga-NOTGA(RGD)3 labeling solution (B). The retention time of radioactivity peak was 
identical to that of Ga-NOTGA(RGD)3 verified by ESI-MS. The UV chromatograms of the 
reaction mixture showed a peak corresponding to NOTGA(RGD)3 (C). 
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(2.5) Lipophilicity study.  
The lipophilicity of [67Ga]Ga-(RGD-Sal)3TAMEol was determined by measuring the Log D7.4 
value using [67Ga]Ga-NOTGA(RGD)3 as a control compound. The Log D7.4 values of [67Ga]Ga-
(RGD-Sal)3TAMEol and [67Ga]Ga-NOTGA(RGD)3 were -3.16 ± 0.03 and -4.10 ± 0.07, 
respectively. 
 
(2.6) Stability of [67Ga]Ga-(RGD-Sal)3TAMEol.  
The stability of [67Ga]Ga-(RGD-Sal)3TAMEol was evaluated in the presence of apo-
transferrin at 37 ˚C. As shown in Table 3, over 95% of the radioactivity derived from [67Ga]Ga-
(RGD-Sal)3TAMEol remained intact after 6 h incubation, demonstrating that [67Ga]Ga-(RGD-
Sal)3TAMEol possessed stability sufficient for in vivo applications. 
 
 
(2.7) Binding affinity to integrin αvβ3.  
The binding affinity of Ga-(RGD-Sal)3TAMEol to integrin αvβ3 on human glioma U87MG 
cells was evaluated with the competitive binding assay using [125I]I-c(RGDyV). The half-maximal 
inhibitory concentration (IC50) values are summarized in Table 4, and the displacement curves of 
[125I]I-c(RGDyV) are presented in Figure 15. The binding affinities of the trivalent probes Ga-
(RGD-Sal)3TAMEol, Ga-NOTGA(RGD)3, and NOTGA(RGD)3 were similar to each other (1.01, 
2.31, and 2.26 nM, respectively) and significantly higher than those of the monovalent ligands. 
The IC50 of the trivalent probes also showed similar values to that of a 99mTc-labeled trivalent RGD 
peptide reported previously.17 The binding affinity of the monovalent RGD-Sal (6.14 nM) was 
higher than that of the monovalent c(RGDyV) (32.27 nM) (Table 4). 
Table 3. Stability of [67Ga]Ga-(RGD-Sal)3TAMEol in apo-transferrin solutiona 
Time (h) Percent of intact radiolabeled complex (%) 
1 98.0 ± 0.4 
3 97.3 ± 0.6 
6 95.7 ± 0. 3 
aExpressed as mean ± s.d. for three experiments. 
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Figure 15. In vitro inhibition curves of [125I]I-c(RGDyV) bound to U87MG glioma 
cells by c(RGDyV), RGD-Sal, NOTGA(RGD)3, Ga-(RGD-Sal)3TAMEol, and Ga-
NOTGA(RGD)3. 
Table 4. IC50 Values of each compound 
design compound IC50, nM 95% C.I. a 
“1 to 3” 
RGD-Sal 6.14 4.92-7.67 
Ga-(RGD-Sal)3TAMEol 1.01 0.74-1.37 
“3 to 3” 
NOTGA(RGD)3 2.26 1.81-2.82 
Ga-NOTGA(RGD)3 2.31 1.80-2.97 
reference c(RGDyV) 32.27 27.1-39.5 
aC.I. = confidential interval. 
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(2.8) Biodistribution studies.  
The biodistribution of radioactivity after injection of [67Ga]Ga-(RGD-Sal)3TAMEol in normal 
mice is summarized in Table 5. [67Ga]Ga-(RGD-Sal)3TAMEol showed rapid blood clearance and 
was excreted mainly in the urine through the kidney.  
The biodistribution of radioactivity at 1 h postinjection in nude mice bearing U87MG xenografts 
was determined in the following 4 samples: (1) RP-HPLC-purified [67Ga]Ga-(RGD-Sal)3TAMEol 
(without RGD-Sal ligand), (2) unpurified [67Ga]Ga-(RGD-Sal)3TAMEol (containing 10 nmol 
ligand), (3) RP-HPLC-purified [67Ga]Ga-NOTGA(RGD)3 (without NOTGA(RGD)3 ligand), (4) 
unpurified [67Ga]Ga-NOTGA(RGD)3 (containing 10 nmol ligand). The results are summarized in 
Table 6. The RP-HPLC-purified [67Ga]Ga-(RGD-Sal)3TAMEol showed that the radioactivity 
levels in the bone, a representative tissue of free gallium accumulation, was low. The tumor uptake 
of RP-HPLC-purified [67Ga]Ga-(RGD-Sal)3TAMEol (4.74 %ID/g) was similar to that of RP-
HPLC-purified [67Ga]Ga-NOTGA(RGD)3 (4.19 %ID/g). The unpurified [67Ga]Ga-
Table 5. Biodistribution of [67Ga]Ga-(RGD-sal)3TAMEol in ddY micea 
 Time (min) 
10 30 60 180 360 
blood      2.80 ± 0.14 1.21 ± 0.04 0.53 ± 0.06 0.07 ± 0.01 0.06 ± 0.01 
liver 1.69 ± 0.07 1.64 ± 0.07 1.33 ± 0.13 1.40 ± 0.09 1.23 ± 0.10 
spleen 2.54 ± 0.18 2.02 ± 0.06 1.63 ± 0.10 1.63 ± 0.17 1.67 ± 0.14 
kidney 12.17 ± 0.64 9.48 ± 0.76 7.69 ± 0.39 5.48 ± 0.18 4.31 ± 0.16 
pancreas 1.11 ± 0.02 0.79 ± 0.03 0.57 ± 0.04 0.45 ± 0.04 0.46 ± 0.02 
heart 2.97 ± 0.22 1.18 ± 0.05 0.83 ± 0.04 0.59 ± 0.06 0.53 ± 0.02 
lung 6.13 ± 0.26  3.34 ± 0.18 2.08 ± 0.10 1.24 ± 0.15 1.29 ± 0.07 
stomachb 0.83 ± 0.05 0.69 ± 0.05 1.01 ± 0.08 0.54 ± 0.04 0.61 ± 0.08  
intestineb 4.71 ± 0.17 3.71 ± 0.12 3.59 ± 0.18 4.07 ± 0.21 4.40 ± 0.41 
muscle 1.12 ± 0.06 0.75 ± 0.12 0.51 ± 0.05 0.32 ± 0.02 0.36 ± 0.01 
urine     48.08 ± 7.30 
feces     0.90 ± 0.05 
a
The results were expressed as percent injected dose per gram (%ID/g) ± SD (n = 5). 
b
Expressed as %ID. 
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NOTGA(RGD)3 showed 60% reduction in the tumor accumulation when compared with the RP-
HPLC-purified [67Ga]Ga-NOTGA(RGD)3 (4.19 %ID/g vs. 1.62 %ID/g). On the other hand, the 
unpurified [67Ga]Ga-(RGD-Sal)3TAMEol indicated only 25% reduction in the tumor 
accumulation when compared with the RP-HPLC-purified [67Ga]Ga-(RGD-Sal)3TAMEol (4.74 
%ID/g vs. 3.59 %ID/g). As a result, the tumor uptake of the unpurified [67Ga]Ga-(RGD-
Sal)3TAMEol was two times higher than that of the unpurified [67Ga]Ga-NOTGA(RGD)3, 
demonstrating the advantage of “1 to 3” design strategy over the conventional “3 to 3” design.  
 
Table 6. Biodistribution at 1 h postinjection in tumor-bearing micea 
 [67Ga]Ga-(RGD-Sal)3TAMEol 
(“1 to 3” design) 
[67Ga]Ga-NOTGA(RGD)3 
(“3 to 3” design) 
 purified unpurified purified unpurified 
ligand (nmol) 0 10 0 10 
blood 0.95 ± 0.01 1.07 ± 0.18 0.38 ± 0.14 0.43 ± 0.12 
liver  4.17 ± 0.57c 2.46 ± 0.52 3.02 ± 0.52d 0.73 ± 0.13 
kidney 11.85 ± 0.34   11.46 ± 0.99 7.90 ± 0.69 6.24 ± 1.16 
spleen 5.01 ± 0.51c 2.19 ± 0.34 3.95 ± 0.44d 0.60 ± 0.26 
intestine b  7.98 ± 1.02c 4.87 ± 0.71 9.91 ± 0.78d 7.95 ± 0.64 
muscle 1.09 ± 0.27 0.72 ± 0.24 1.05 ± 0.40 0.62 ± 0.12 
bone 2.48 ± 0.24c 1.26 ± 0.17 1.38 ± 0.23 n.d. 
tumor  4.74 ± 0.40c 3.59 ± 0.16 4.19 ± 0.24d 1.62 ± 0.35 
aThe results were expressed as percent injected dose per gram (%ID/g) ± SD (n=4-5). bExpressed 
as %ID. Statistical analysis was performed using one-way analysis of variance followed by 
Tukey’s multiple-comparison test; c(different from unpurified [67Ga]Ga-(RGD-Sal)3TAMEol, 
p<0.05), d(different from unpurified [67Ga]Ga-NOTGA(RGD)3, p<0.05). n.d.; not determined. 
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(2.9) Small animal SPECT/CT imaging.  
Figure 16 shows the SPECT/CT images of tumor-bearing mice of the unpurified [67Ga]Ga-
(RGD-Sal)3-TAMEol and the unpurified [67Ga]Ga-NOTGA(RGD)3 over 45-75 min postinjection. 
The tumor was clearly visualized after injection of ([67Ga]Ga-(RGD-Sal)3TAMEol) prepared from 
the “1 to 3” design, while the tumor was barely visualized with [67Ga]Ga-NOTGA(RGD)3 from 
the “3 to 3” design. These images correlated well with the biodistribution results at the similar time 
point (Table 6).  
 
[Discussion] 
In the design of multivalent probes for targeting integrin αvβ3, the distance between each RGD 
motif plays a crucial role in eliciting the multivalent effect. Previous studies indicated the optimum 
distances between each RGD moiety is 25-30 bonds.39–42 Therefore, I introduced a hexanoate 
linker between RGD and Sal to adjust the recommended distance (28 bonds after complex 
formation). 
Initially, I tried to isolate the trivalent Schiff base ligand, (RGD-Sal)3TAMEol. However, I could 
not isolate (RGD-Sal)3TAMEol because of the instability of (RGD-Sal)3TAMEol in aqueous 
solution. Therefore, [67Ga]Ga-(RGD-Sal)3TAMEol was prepared by mixing RGD-Sal, TAMEol, 
and Ga, simultaneously. The RP-HPLC analysis of the reaction solution of [67Ga]Ga-(RGD-
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. SPECT/CT images of U87MG tumor-bearing nude mice over 45−75 min 
post i.v. injection of (A) 1.8 MBq of the unpurified [67Ga]Ga-(RGD-Sal)3TAMEol 
(100 µL, [RGD-Sal] = 10 nmol) and (B) 2.2 MBq of the unpurified [67Ga]Ga-
NOTGA(RGD)3 (100 µL, [NOTGA(RGD)3] = 10 nmol). Images are shown at the 
same signal intensity scale. Red arrow indicates the U87MG tumor. 
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Sal)3TAMEol by UV trace showed two peaks corresponding to the monovalent RGD-Sal and 
benzyl alcohol, a preservative in [67Ga]Ga-citrate, and the intact trivalent ligand, (RGD-
Sal)3TAMEol, was not observed (Figure 13C). As mentioned in Chapter 1, these results again 
indicated that the Schiff base ligand (RGD-Sal)3TAMEol was rapidly decomposed to its 
constituents by the changes in the equilibrium during RP-HPLC analysis, while the Schiff base 
stabilized by 67Ga coordination provided stable [67Ga]Ga-(RGD-Sal)3TAMEol. These results 
indicated that the metal coordination-mediated stabilization of Schiff base chelator constitutes a 
useful procedure to synthesize 67/68Ga-labeled trivalent probes. After removing the unlabeled 
ligand by RP-HPLC, [67Ga]Ga-(RGD-Sal)3TAMEol was obtained at the radiochemical purity over 
99% and remained stable in apo-transferrin solution for 6 h (Table 3), confirming that [67Ga]Ga-
(RGD-Sal)3TAMEol provides a kinetically stable 67Ga-labeled complex.  
The binding affinity of the monovalent RGD-Sal (6.14 nM) was higher than that of the 
monovalent c(RGDyV) (32.27 nM) (Table 4). After reducing the aldehyde of salicylaldehyde in 
RGD-Sal to alcohol, the binding affinity became similar to c(RGDyV) peptide (data not shown). 
Therefore, the high binding affinity of RGD-Sal would be attributable to the non-specific binding 
of the aldehyde group to amine groups of the protein. The trivalent Ga-(RGD-Sal)3TAMEol (1.01 
nM) acquired higher integrin αvβ3 binding affinity than RGD-Sal (6.14 nM). Since the binding 
affinity of Ga-NOTGA(RGD)3 (2.31 nM) was similar to that of NOTGA(RGD)3 (2.26 nM), the in 
vivo competition of the monovalent RGD-Sal against the trivalent Ga-(RGD-Sal)3TAMEol would 
be less than that of the trivalent NOTGA(RGD)3 against the trivalent Ga-NOTGA(RGD)3. 
In the biodistribution study using normal mice, [67Ga]Ga-(RGD-Sal)3TAMEol showed rapid 
blood clearance and was excreted to urine via kidney (Table 5). This result was similar to other 
RGD compounds.43,44  
When the 67Ga-labeled probes were administered into U87MG tumor-bearing nude mice, the 
RP-HPLC-purified [67Ga]Ga-(RGD-Sal)3TAMEol showed low radioactivity levels in bone (Table 
6), a known tissue of free 67Ga accumulation.9,45 These results confirmed that [67Ga]Ga-(RGD-
Sal)3TAMEol possess stability sufficient for in vivo applications. The RP-HPLC-purified 
[67Ga]Ga-(RGD-Sal)3TAMEol and [67Ga]Ga-NOTGA(RGD)3 showed similar tumor uptakes 
(4.74 ± 0.40 and 4.19 ± 0.24 %ID/g, respectively), reflecting the similar binding affinities to the 
U87MG cells (Table 4) and the high in vivo stability of the two 67Ga-labeled probes. 
Biodistribution of [67Ga]Ga-NOTGA(RGD)3 without post-labeling purification, which represents 
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a scenario where a 67Ga-labeled probe is administered into subjects with excess of unlabeled 
trivalent ligand was also evaluated. To allow direct comparison with [67Ga]Ga-(RGD-
Sal)3TAMEol, similar amount of the unlabeled ligand was co-injected into mice. According to the 
previous reports, in many kind of chelators, 100 µM concentration of ligand is enough to obtain 
67/68Ga-labeled compounds with over 95% radiochemical yield.22,46 Since 100 µL of radiolabeling 
solution was injected into mouse, the amount of the unlabeled ligand was adjusted to 10 
nmol/mouse. The tumor accumulation of [67Ga]Ga-NOTGA(RGD)3 was inhibited by 60% in the 
presence of 10 nmol of NOTGA(RGD)3. On the other hand, as low as 25% reduction of the tumor 
accumulation was observed after injection of [67Ga]Ga-(RGD-Sal)3TAMEol in the presence of 10 
nmol of RGD-Sal and 2.7 nmol of TAMEol, which indicates that the free trivalent (RGD-
Sal)3TAMEol present as an equilibrium in the injectate was rapidly decomposed to the monovalent 
RGD-Sal and TAMEol upon injection, as also observed in the RP-HPLC analysis (Figure 13). 
Some RGD-Sal may have bound to plasma proteins through the aldehyde group, which may also 
reduce the inhibitory action of the monovalent RGD-Sal on tumor cells. Such characteristics of 
[67Ga]Ga-(RGD-Sal)3TAMEol were well reflected in the SPECT/CT images where [67Ga]Ga-
(RGD-Sal)3TAMEol depicted clear tumor images in the presence of the unlabeled monovalent 
ligand, RGD-Sal whereas [67Ga]Ga-NOTGA(RGD)3 showed poorly tumor images in the presence 
of unlabeled trivalent ligand, NOTGA(RGD)3 (Figure 16). These results demonstrated that the 
coordination-mediated stabilization of Schiff base chelator constitutes a useful procedure to apply 
the chemical design achieved with 99mTc-labeled trivalent probes to 68Ga-labeled ones. 
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[Summary] 
The target binding affinity and the pharmacokinetics of the 67Ga-labeled Schiff base ligand 
conjugated with RGD were conducted to evaluate the present molecular design of the 
coordination-mediated synthesis of multivalent 67/68Ga-labeled probes. [67Ga]Ga-(RGD-
Sal)3TAMEol possessed the stability sufficient for in vivo application and Ga-(RGD-
Sal)3TAMEol possessed the binding affinity to integrin αvβ3 similar to that of a trivalent probe, 
Ga-NOTGA(RGD)3. Since the Schiff base ligand was rapidly decomposed upon injection, the 
competitive inhibition of the unlabeled ligands against the trivalent 67Ga-labeled probes was low. 
As a result, SPECT/CT imaging of [67Ga]Ga-(RGD-Sal)3TAMEol visualized murine tumor 
images more clearly compared to that of [67Ga]Ga-NOTGA(RGD)3. The present study indicates 
that the use of the Schiff base ligand would constitute a useful procedure to prepare 67Ga-labeled 
purification-free trivalent probes. 
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[Conclusions] 
 I investigated the way to apply the coordination-mediated synthesis of multivalent probes 
developed with 99mTc-labeled probes to 67/68Ga-labeled ones. Hdpp, a bidentate chelator, failed to 
prepare 67Ga-labeled probes since high Hdpp concentration was needed to maintain the intact 
structure of the radiometal chelate. PTSC derivatives, tridentate chelators, provided 67Ga-labeled 
probes of much higher stability than that from Hdpp. However, the radiolabeled probes still 
suffered from insufficient stability for in vivo applications, and further structural modification was 
required. Contrary to these approaches, the Schiff base chelator provided 67Ga-labeled trivalent 
probes with stability sufficient for in vivo applications. Furthermore, (RGD-Sal)3TAMEol 
exhibited the much less inhibitory effect on the [67Ga]Ga-(RGD-Sal)3TAMEol accumulation to 
the target molecules compared with [67Ga]Ga-NOTGA(RGD)3 prepared under the conventional “3 
to 3” approach, due to rapid decomposition of (RGD-Sal)3TAMEol to RGD-Sal and TAMEol after 
injection. As a result, [67Ga]Ga-(RGD-Sal)3TAMEol visualized the murine tumor without post-
labeling purification. The present study indicates that the metal-coordination mediated synthesis 
of 67/68Ga-labeled probes was successfully achieved to a 67Ga-labeled probe through the use of a 
Schiff base ligand. A new chemical procedure to prepare purification-free 67/68Ga-labeled probes 
for imaging the saturable systems of the body was established. The present findings would 
facilitate the applications of 68Ga-labeled probes to molecular imaging with PET. 
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[Experimental section] 
General. [67Ga]Ga-citrate and [67Ga]GaCl3 was purchased from FUJIFILM RI Pharma Co., Ltd. 
(Tokyo, Japan). Mass spectrometry was carried out using an Agilent 6130 Series Quadrupole 
LC/MS electrospray system (Agilent Technologies, Tokyo) or JMS-T100LP (JEOL Ltd., Tokyo). 
1H-NMR spectra were recorded on a JEOL JNM-ECS-400 (400 MHz) spectrometer (JEOL Ltd.). 
The melting points were measured using a MP-500D (Yanaco, Kyoto, Japan) and were reported 
uncorrected. Methyl 3-[1-(2-pyridyl)ethylidene]hydrazinecarbothioate were synthesized 
according to the procedures reported previously.26 All commercially available chemicals were of 
analytical grade and used without further purification. All compounds purity used in affinity 
assays, biodistribution studies and SPECT studies was greater than 95%. Analytical RP-HPLC 
was performed with a Cosmosil 5C8 MS column (4.6 × 150 mm, Nacalai Tesque Inc., Kyoto, 
Japan) at a flow rate of 1 mL/min with a gradient mobile phase starting from 70% A (Milli-Q water 
containing 0.1% trifluoroacetic acid (TFA)) and 30% B (methanol containing 0.1% TFA) to 30% 
A and 70% B at 60 min (system 1), starting from 90% A and 10% B to 20% A and 80% B at 30 
min (system 2), or starting from 100% C (10 mM acetate buffer pH 4.5) and 0% D (acetonitrile) 
to 95% C and 5% D at 10 min and to 90% C and 10% D at 20 min (system 3). Or analytical RP-
HPLC was performed with a TSKgel TMS250 column (4.6 × 75 mm, TOSOH Inc, Tokyo) at a 
flow rate of 0.8 mL/min with a 0.1 M Tris-HNO3 buffer (pH 7.0)/acetonitrile (95/1) (system 4). 
Or analytical RP-HPLC was performed with a Unison US-C18 (4.6 × 150 mm, Imtakt Inc., Kyoto, 
Japan) at a flow rate of 1 mL/min with a gradient mobile phase starting from 50% E (5 mM 
ammonium acetate) and 50% F (methanol) to 0% E and 100% F at 30 min (system 5) or starting 
from 30% E and 70% F to 0% E and 100% F at 30 min (system 6). Preparative RP-HPLC was 
performed with a Cadenza 5CD-C18 column (20 × 150 mm, Imtakt Inc.) with a guard column 
(Cadenza 5CD-C18 10 × 8 mm) at a flow rate of 5 mL/min with a gradient mobile phase starting 
form 60% A and 40% B to 20% A and 80% B in 30 min (system 7) or starting from 60% G (10 
mM NH4HCO3/MilliQ water) and 40% F to 30% G and 70% F at 30 min (system 8). Or preparative 
RP-HPLC was performed with a Mightysil RP-8 column (GP 20 × 250 mm, Kanto Chemical Inc., 
Tokyo, Japan) at a flow rate of 5 mL/min with a gradient mobile phase starting form 60% A and 
40% B to 30% A and 70% B in 60 min (system 9). The eluent was monitored online with a 
UV/Visible single beam spectroscopy detector (L-7450, Hitachi Co. Ltd., Tokyo) coupled to a 
NaI(Tl) radioactivity detector (Gabi star, Raytest, Strubenhardt, Germany) or ICP-MS (Agilent 
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5400 ICP-MS, Agilent Technologies. TLC analyses were performed with silica plates (Silica gel 
60F254, Merck Ltd., Tokyo). Cellulose acetate electrophoresis (CAE) strips were run in a veronal 
buffer (pH 8.5, I=0.06) at constant current of 1 mA/cm for 30 min. Radioactivity was measured 
using a MiniGita Star Gamma TLC Scanner (raytest) and an auto well gamma counter. 
Synthesis of c[R(Pbf)GD(tBu)fK] 
1. Solid phase peptide synthesis 
Peptide-bound resin was prepared using H-Gly-Trt(2-Cl) Resin (376 mg, 0.3 mmol) as starting 
material for Fmoc coupling method, 2.5 equivalent of protected amino acid Fmoc-Arg(Pbf)-OH, 
2.5 equivalent N,N’-diisopropylcarbodiimide (DIC) and 2.5 equivalent of 1-hydroxybenzotriazole 
(HOBt) was stirred in DMF (5 mL) for 3 hr. Completion of the coupling reaction was confirmed 
by Kaiser test. Deprotection of N-terminal of the Fmoc group was performed by 20% 
piperidine/DMF. Fmoc-Lys (Z)-OH, Fmoc-D-Phe-OH end by Fmoc-Asp(tBu)-OH sequentially 
added by repeating the same operation. Resin bound linear peptide was obtained (A). 
2. Cleavage of resin 
Compound (A), a mixture of acetic acid, 2,2,2-trifluoroethanol and CH2Cl2 (3: 1: 6, v/v/v, in 5 ml) 
was stirred at room temperature for 3 hours. After removal of the resin, vacuum evaporation of the 
filtrate, linear peptide (B) was obtained as a white solid (244.6 mg, 93%). ESI-MS, m/z: 1086.5 
[(M + Na)+]; Found: 1086.45. 
3. Cyclization of linear peptide 
Compound (B) (311 mg, 0.292 mmol) was dissolved in DMF (58 mL). NaHCO3 (125 mg, 1.45 
mmol) was added and stirred vigorously. Diphenylphosphoryl azide (DPPA, 188 μl, 0.87 mmol) 
was added slowly and stirred for 24 hours at room temperature. After removing the NaHCO3 by 
filtration, the solvent was evaporated under reduced pressure. Residue afterwards precipitated by 
admixing of CH2Cl2 (5 mL) and sat. NaHCO3 (8 mL), and shaked vigorously. The resulting white 
precipitate was collected by filtration, washed with water (3 x 10 mL) and Et2O (3 x 10 mL). 
Cyclized peptides (C) as a white solid was obtained (252.4 mg, 82%) ESI-MS, m/z:1046.5 [(M + 
H)+], Found 1046.62. 
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4. Deprotection of Z group 
Compound (C) (252 mg, 0.24 mmol) was dissolved in dimethylacetamide (DMAC, 5 mL), 10% 
palladium/carbon (Pd/C) (125 mg, 1.174 mmol) was added and the solution was stirred at room 
temperature for 4 h under H2 atmosphere. After reducing the solvent in vacuo, Pd/C was suspended 
in MeOH and removed by filtration. The solvent was removed under reduced pressure, then 
admixing CH2Cl2 (5 mL) and hexane (5 mL). The mixture evaporated in vacuum to obtaine 
c[R(Pbf)GD(tBu)fK] as white yellowish solid (201 mg, 92%). ESI-MS, m/z: 912.46 [(M + H)+] ; 
Found 912.41. 
Synthesis of 2,2’,2”-tri(aminomethyl)ethanol/3HCl (TAMEol). Pentaerythritol tribromide 
(2.08 g, 6.40 mmol) and sodium azide (4.8 g, 73.8 mmol) were dissolved in dimethylformamide 
(DMF, 35 mL) and mixed at 80 ˚C for 24 h under N2 atmosphere. After the solvent was removed 
in vacuo, the residue was resolved in H2O (20 mL) and then extracted with Et2O (30 mL). The 
organic layer was dried over anhydrous MgSO4. After removing the solvent, pentaerithritol 
triazide was obtained as a colorless oil. This product was used without further purification. 
Pentaerithritol triazide was dissolved in MeOH (10 mL), and then 10% Pd/C (1.03 g) was added 
portion-wise. After the mixture was stirred for 7 h, Pd/C was removed by filtration. After the 
solvent was evaporated in vacuo, a colorless transparent oil was obtained. The resulting oil was 
dissolved in the solution (20 mL, sat. NaHCO3 : acetonitrile/1 : 1) and then di-tert-butyl 
dicarbonate (Boc2O, 5.79 g, 26.5 mmol) dissolved in acetonitrile (20 mL) was added dropwise on 
ice. After mixing for 15 h, the solvent was evaporated in vacuo and then the residue was purified 
with open column chromatography using silica gel and subsequently eluted with CHCl3 : Et2O/20 
: 1 to obtain N,N,N-(tert-butoxycarbonyl)-2,2’,2”-tri(aminomethyl)ethanol (TAMEol-Boc3). 
TAMEol-Boc3 was dissolved in 4 M HCl/EtOAc (5 mL) and mixed for 150 min. After removing 
the solvent in vacuo, HCl salt of compound TAMEol was obtained as a white solid (190 mg, 12%). 
1H-NMR (D2O), (ppm): 3.18 (t, 6H, CH2), 3.75 (s, 2H, CH2). ESI-MS, m/z: 134 [M+H]+, Found 
134. M.p. 315-316 ˚C. 
Synthesis of Ga-(3-hydroxy-1,2-dimethyl-4-pyridone)3 (Ga-(Hdpp)3) (1). 3-Hydroxy-1,2-
dimethyl-4-pyridone (Hdpp, 30 mg, 0.22 mmol) was suspended in water (5 mL). GaCl3 (12 mg, 
0.073 mmol) dissolved in water (50 µL) was added to the solution and then the solution became 
clear. After the pH of the solution was adjusted to 9 by 2 N NaOH, the reaction mixture was heated 
at 70˚C until the reaction volume was < 2.5 mL. After cooling to room temperature, the precipitate 
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was collected by filtration and then Ga-(Hdpp)3 was obtained as an orange solid (20.6 mg, 56%). 
ESI-MS, m/z: 484 [M+H]+, Found 484. 
Synthesis of 2-acetylpyridine thiosemicarbazone-1 (PTSC-1) (2). 0.89 mmol of bis(2-
methoxyethyl)amine was added to 200 mg (0.89 mmol) of methyl 3-[1-(2-
pyridyl)ethylidene]hydrazinecarbothioate dissolved in 2.2 mL of EtOH. The solution was heated 
under reflux for 24 h. After cooling to room temperature, the resulting crystals were collected, 
washed with EtOH (30 mL) to afford PTSC-1 (2): (82.2 mg, 30.1%). 1H-NMR (CD3OD), 𝛿: 2.44 
(m, 3H, CH3), 3.37 (m, 6H, OCH3), 3.75 (m, 4H, CH2O), 4.01 (s, 4H, NCH2), 7.47 (m, 1H, Pyr), 
8.03 (m, 2H, Pyr), 8.62 (m, 1H, Pyr). ESI-MS, m/z: 310 [M+H]+, Found 310. 
Synthesis of 2-acetylpyridine thiosemicarbazone-2. (PTSC-2) (3). 0.89 mmol of 
diisobutylamine was added to 200 mg (0.89 mmol) of methyl 3-[1-(2-
pyridyl)ethylidene]hydrazinecarbothioate dissolved in 2.2 mL of EtOH. The solution was heated 
under reflux for 24 h. After cooling to room temperature, the resulting crystals were collected, 
washed with EtOH (30 mL) to afford PTSC-2 (3): (101 mg, 37.5%) 1H-NMR (CD3OD), 𝛿: 0.95  
(m, 12H, CH3), 2.46 (s, 3H, CH3), 3.69 (m, 4H, CH2), 7.47 (m, 1H, Pyr), 7.94 (m, 2H, Pyr), 8.65 
(m, 1H, Pyr). ESI-MS, m/z: 306 [M+Na]+, Found 307. 
Synthesis of Ga-(PTSC-1)2 (4). Compound 2 (20 mg) and Ga(NO3)3/nH2O was dissolved in 
EtOH (0.5 mL) and mixed at 40 ˚ C for 1 h. A solution of ammonium hexafluorophosphate (13 mg, 
0.08 mmol) in EtOH (200 µL) was added to the solution. After mixing for 10 min, the precipitates 
were obtained by filtration to afford compound 4 : 7.5 mg (17.1%). ESI-MS, m/z: 687 [M]+, Found 
687.  
Synthesis of Ga-(PTSC-2)2 (5). Compound 3 (20 mg) and Ga(NO3)3/nH2O was dissolved in 
EtOH (0.5 mL) and mixed at 40 ˚ C for 1 h. A solution of ammonium hexafluorophosphate (13 mg, 
0.08 mmol) in EtOH (200 µL) was added to the solution. After mixing for 10 min, the precipitates 
were obtained by filtration to afford compound 5 : 4.3 mg (9.7%). ESI-MS, m/z: 679 [M]+, Found 
679. 
Synthesis of 2,2’,2”-tri(salicyliminoethyl)ethanol ((Sal)3TAMEol, 7). TAMEol/3HCl (170 
mg, 0.70 mmol) and salicylaldehyde (6) (489 mg, 4.00 mmol) was dissolved in MeOH (10 mL). 
After standing overnight, the solvent was removed in vacuo. The residue was recrystallized from 
MeOH to afford (Sal)3TAMEol (7) as a yellow solid (83 mg, 27%).1H-NMR (CD3OD), (ppm): 
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3.72 (s, 6H, CH2), 3.75 (s, 2H, CH2), 6.89 (t, 3H, CH), 8.41 (s, 3H, CH=N). ESI-MS, m/z: 446 
[M+H]+, Found 446. 
Synthesis of Ga-(Sal)3TAMEol (8). Compound 7 (12.8 mg, 28.8 µmol) and gallium-
acetylacetonate (10.5 mg, 28.6 µmol) was dissolved in EtOH (8.5 mL) and then refluxed at 80 ˚C 
for 12 h. The precipitate was collected by filtration and then compound 8 was obtained as a pale 
yellow solid (8 mg, 54%). ESI-MS, m/z: 512 [M+H]+, Found 512. 
Synthesis of 3-formyl-4-hydroxybenzoic Acid (9). p-Hydroxybenzoic acid (1.97 g, 14.3 
mmol) was dissolved in trifluoroacetic acid (TFA, 6 mL). Hexamethylenetetramine (2.0 g, 14.3 
mmol) dissolved in TFA (8 mL) was added to the solution dropwise and mixed at 70 ˚C for 22 h. 
After cooling to room temperature, 4 N HCl aq. (45 mL) was added to the solution and mixed for 
6 h. The precipitate was collected and washed with H2O (400 mL) to obtain compound 9 as a pale 
yellow solid (1.3 g, 55%). 1H-NMR (CD3OD), 𝛿: 7.02 (d, 1H, Aryl), 8.15 (dd, 1H, Aryl), 8.40 (s, 
1H, Aryl), 10.11 (s, 1H, CHO). ESI-MS, m/z: 167 [M+H]+, Found 167. M.p. 225-227 ˚C. 
Synthesis of 3-[(2-hydroxyphenylimino)-methyl]-4-hydroxybenzoic acid (10). Compound 9 
(503 mg, 3.03 mmol) and o-aminophenol (330 mg, 3.02 mmol) were dissolved in MeOH (30 mL) 
and refluxed at 70 ˚C for 10 min. Compound 10 was crystallized from MeOH (543 mg, 70%). 1H-
NMR (CD3OD), 𝛿: 6.94 (m, 3H, Aryl), 7.18 (m, 1H, Aryl), 7.47 (m, 1H, Aryl), 8.11 (t, 1H, Aryl), 
8.24 (s, 1H, Aryl), 9.02 (s, 1H, CHN). ESI-MS, m/z: 258 [M+H]+, Found 258. M.p. 259-260 ˚C. 
Synthesis of Fmoc-6-aminohexanoic acid (11). 6-Aminohexanoic acid (1.25 g, 9.53 mmol) 
was dissolved in H2O (20 mL) and then 10% NaHCO3 solution (20 mL) was added. N-(9-
fluorenylmethoxycarbonyloxy) succinimide (Fmoc-OSu, 3.56 g, 10.6 mmol) dissolved in dioxane 
(20 mL) was added to the solution at 0 C and mixed overnight. After removing the solvent in 
vacuo, 1 N HCl aq. (10 mL) was added and then extracted by CH2Cl2 (20 mL × 3). The organic 
solvent was dried over MgSO4. Compound 11 was recrystallized from CH2Cl2 and obtained as a 
white solid (2.4 g, 71%). 1H-NMR (CDCl3), 𝛿: 1.51 (m, 6H, CH2), 2.34 (m, 2H, CH2CO), 3.17 (m, 
2H, CH2NH), 4.19 (t, 1H, CH), 4.41 (m, 2H, CH2), 4.77 (br, 1H, NH), 7.33 (m, 4H, Fmoc), 7.57 
(d, 2H, Fmoc), 7.74 (d, 2H, Fmoc). ESI-MS, m/z: 376 [M+Na]+, Found 376. M.p. 117-118˚C. 
Synthesis of Fmoc-6-aminohexanoic acid 2,3,5,6-tetrafluorophenyl ester (12). Compound 
11 (1.01 g, 2.86 mmol), 2,3,5,6-tetrafluorophenol (TFP, 540 mg, 3.25 mmol) was dissolved in 2 
mL of DMF. N, N'-dicyclohexylcarbodiimide (DCC, 670 mg, 3.25 mmol) in 0.7 mL of DMF was 
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added dropwise at 0 ˚C under argon atmosphere. After stirring for 24 h, the resulting DC-urea was 
filtered off and the solvent removed in vacuo. The residue was purified by preparative TLC (CHCl3 
: AcOEt/10:1) to obtain compound 12 as a white solid (0.99 g, 69%). 1H-NMR (CDCl3), 𝛿: 1.49 
(m, 6H, CH2), 2.67 (t, 2H, CH2CO), 3.21 (m, 2H, CH2NH), 4.20 (m, 1H, Fmoc), 4.39 (d, 2H, CH2), 
4.76 (br, 1H, NH), 6.97 (m, 1H, TFP), 7.34 (dd, 4H, Fmoc), 7.57 (d, 2H, Fmoc), 7.75 (d, 2H, 
Fmoc). ESI-MS, m/z: 524 [M+Na]+, Found 524. M.p. 102 ˚C. 
Synthesis of Fmoc-6-aminohexanoate-c[R(Pbf)GD(tBu)fK] (13). c(R(Pbf)GD(tBu)fK) (230 
mg, 0.252 mmol) was dissolved in 300 µL of DMF. After compound 12 (161 mg, 0.321 
mmol) was added slowly, then the solution was stirred at room temperature for 2 h under argon 
atmosphere. After removing the solvent in vacuo, the residue was purified by preparative TLC 
using CHCl3 : MeOH/10 : 1 as a solvent. Compound 13 was obtained as a white solid (206 mg,  
66%). ESI-MS, m/z: 1269 [M+Na]+, Found 1269. M.p. 201-202 ˚C. 
Synthesis of 6-aminohexanoate-c[R(Pbf)GD(tBu)fK] (14). Compound 13 (156 mg, 0.125 
mmol) was dissolved in 5 mL of 20% piperidine/DMF and stirred at room temperature for 25 
min. After the solvent was removed in vacuo, the residue was dissolved in a small amount of 
MeOH. An excess of Et2O was added to the solution and then the resulting precipitate was 
collected by filtration. The precipitate was washed with CH2Cl2 (5 mL) and hexane (5 mL) to 
obtain compound 14 as a white solid (118 mg, 92%). ESI-MS, m/z: 1025 [M+H]+, Found 1025. 
M.p. 208-209 ˚C.  
Synthesis of Sal-Ahx-cR(Pbf)GD(tBu)fK (15). Compound 14 (13 mg, 12.7 µmol), compound 
10 (5 mg, 19 µmol), 1-hydroxy-7-azabenzotriazole (HOAt, 10 mg, 73 µmol) was dissolved in 
DMF (200 µL) and stirred. Then, DCC (6 mg, 29 µmol) dissolved in DMF (300 µL) was added 
dropwise at 0 ˚C under argon atmosphere. After stirred for 48 h at room temperature, the resulting 
DC-urea was filtered off and the solvent was removed in vacuo. The residue was purified by 
preparative TLC with CHCl3 : MeOH/10 : 1 as a solvent to obtained compound 15 as a yellow-red 
solid (13 mg, 81 %). ESI-MS, m/z: 1286 [M+Na]+, Found 1286. M.p. 198-199 ˚C. 
Synthesis of Sal-Ahx-cRGDfK (16, RGD-Sal). Compound 15 (14 mg, 0.011 mmol) was 
dissolved in 5 mL of TFA : H2O/9 : 1 solution. The solution was stirred for 3 h at room temperature. 
After the solvent was removed in vacuo, the residue was dissolved in water (5 mL) and washed 
with CHCl3 (3 × 5 mL). The aqueous layer was purified by preparative RP-HPLC (system 7) to 
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obtain compound 16 (8.0 mg, 84%). ESI-MS, m/z: 887 [M+Na]+, Found 887. HRMS, m/z: 
865.42083 [M+H]+ calculated for C41H57N10O11, Found 865.42484. M.p. 217 ˚C (dec). 
Synthesis of Ga-(RGD-Sal)3TAMEol (17). Compound 16 (5.6 mg, 6.5 µmol) and 
TAMEol/3HCl (266 µg, 1.1 μmol) was dissolved in 1 M ammonium acetate solution (400 µL) and 
then the pH of the solution was adjusted to 8 with 25% aqueous ammonia (solution 1). GaCl3 (5 
mg/mL) in 50 mM HCl aq was mixed with 1 M ammonium acetate solution and then the pH of 
the solution was adjusted to 8 with 25% aqueous ammonia (solution 2, final GaCl3-concentration: 
0.45 mg/mL). Solution 2 (440 µL) was added to solution 1 and stirred for 8 h at 70 ˚C while the 
pH of the solution was maintained at 8 with 25% aqueous ammonia. The solution was purified by 
preparative RP-HPLC (system 9) to obtain compound 17 (2.5 mg, 83%). ESI-MS, m/z: 914 
[M+3H]3+, Found 914. 
Synthesis of L-Glutamic acid-5-bromo benzyl ester (18). L-Glutamic acid-5-benzyl ester (1 
g, 4.33 mmol) and sodium bromide (1.5 g, 14.75 mmol) were dissolved in 1 N hydrobromic acid 
15 mL (7.67 mmol) and cooled to 0 ˚C. Sodium nitrite (500 mg, 7.67 mmol) was added portion 
wise and stirred for 2 hours at 0 ˚C, then conc. sulfuric acid (500 µL) was added followed by Et2O. 
The water phase was three times extracted with Et2O and the combined organic phases were 
extracted with brine four times, dried over Na2SO4 and concentrated. The residue was purified by 
column chromatography (silica gel 50, hex:EtOAc 5:1) to obtain compound 18 (800 mg, 50.4%). 
1H NMR (CDCl3).  (ppm): 9.86 (s, 1H, COOH), 7,26 (m, 5H, Phe) 4.30-4.33 (dd, 1 H, CH-Br), 
2.46-2.58 (m, 2H, CH-CH), 2.17-2.39 (m-m, 2H, CH-CH). ESI-MS, m/z: 322.94 [(M + Na)+]; 
Found: 322.94. 
Synthesis of α-bromoglutaric acid 1-tert-butyl-5-benzyl ester (19). Compound 18 (0.8 g, 5.64 
mmol) were dissolved in CHCl3 (8 ml), then tert-butyl 2,2,2-trichloroacetimidate (TBTA) (3.1 g, 
14.2 mmol) was added portionwise to the solution followed by DMAC (1.5 ml) and 
borontrifluoride-etherate (107 µl). The mixture was stirred for 3 days at room temperature. After 
concentrated in vacuo, the residue was extracted by hexane (3 x 7 ml) and purified by column 
chromatography (Hexane: EtOAc, 5:1) to obtain compound 19 as colorless oil (1.281 g, 61%). 1H 
NMR (CDCl3).  (ppm): 7.32 (m, 5H, Ar); 5.02 (s, 2H, CH-Phe); 2.4 (td, 2H, CH2-COOBz); 2.01- 
1.79 (m, 2H, CH2-Br); 1.56 (s, 9H, COOtBu). ESI-MS, m/z: 379.04 [(M+Na)+]; Found: 379.04. 
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Synthesis of 1,4,7-tris-(1-tert-butoxycarbonyl-3-benzyloxycarb-ony-propyl)-1,4,7 
triazacyclononane (NOTGA-tBu3-Bz3) (20). Compound 19 (1.3 g, 3.64 mmol) was dissolved in 
3.5 mL of acetonitrile and added dropwise to a solution of 1,4,7-triazacyclononane (0.142 g, 1.10 
mmol) in 3.3 mL acetonitrile with K2CO3 (0.913 g, 6.62 mmol) during 2 h at 0 ˚C under N2. The 
mixture was stirred at room temperature for 24 h. The reaction mixture was filtrated and the solvent 
was evaporated in vacuo. The residue was dissolved in dichloromethane (15 mL) and washed with 
5% of NaHCO3 (3 × 10 mL), and the organic layer was dried over MgSO4. After removing the 
solvent in vacuo, the residue was purified with open column chromatography using silica gel and 
subsequent elution with chloroform/ acetone (50:1) to afford compound 20 as a yellowish oil 
(0.637 g, 69%). 1H NMR (400 MHz, CDCl3), δ (ppm): 7.24−7.39 (m, 15H, Ph); 5.07 (s, 6 H, 
CH2−Ph); 3.09−3.13 (t, 3H, N−CH); 2.68, 2.95 (d, J = 0.031, 12H, N-CH2-CH2-N); 2.53−2.42 (m, 
6H, CH2−COOBz); 1.82−2.03 (m-m, 6H, N-CH-CH2); 1.43 (s, 27H, C(CH3)3). ESI-MS, m/z: 
958.54 [M+H]+, Found 958.65. 
Synthesis of 1,4,7-(α-bromoglutaric acid 1-tert-butyl-5-benzyl ester)-1,4,7-
triazacyclononane (NOTGA-tBu3) (21). Compound 20 (170 mg, 0.177 mmol) were dissolved in 
methanol/water (5:1) and then 10% Pd/C (127 mg) was added portion-wise. The mixtures were 
stirred for 12 h under H2 atmosphere, then filtered over celite, and evaporated to obtain compound 
21 as white solid (95 mg, 78.01%). 1H NMR (400 MHz, CD3OD), δ(ppm): 3.59−3.93 (br, 3H, 
N−CH); 3.08−3.11 (br, 12H, N−CH2−CH2−N); 2.49−2.58 (br, 6H, CH2−COOH); 1.98−2.13 (br, 
6H, N− CH−CH2); 1.50 (s, 27H, C(CH3)3). ESI-MS, m/z: 688.39 [M + 3H]3+; Found: 688.48. 
Synthesis of NOTGA-(tBu)3-[Ahx-c(R(Pbf)GD(tBu)fK)]3 (22). Compound 21 (12 mg, 17.5 
µmol) and TFP (28 mg, 169 µmol) were dissolved in CH2Cl2 (350 µL) and then DCC (17 mg, 82 
µmol) dissolved in CH2Cl2 (100 µL) was added to the solution at 0 ˚C under N2 atmosphere. After 
mixing for 12 h, the white precipitates were removed by filtration. The solvent was evaporated and 
then the residue was dissolved in DMF (400 µL). After compound 14 (54 mg, 52.7 µmol) was 
added to the solution, the solution was mixed for 24 h. The white precipitate was obtained after 
excess of Et2O was added to the solution. The white precipitate was purified by preparative TLC 
(CHCl3 : MeOH/5 : 1) to obtain compound 22 (46.6 mg, 72%). ESI-MS, m/z: 1877 [M+2Na]2+, 
Found 1877.  
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Synthesis of NOTGA(RGD)3 (23). Compound 22 (46 mg, 12.4 µmol) were dissolved in 5 mL 
of TFA : triethylsilane : H2O/9.5 : 0.25 : 0.25 and then stirred at room temperature for 16 h. After 
removing the solvent in vacuo, the residue was dissolved in MeOH : H2O/3 : 7 (10 mL) and then 
washed by CHCl3 (3 × 10 mL). Aqueous phase was purified with preparative RP-HPLC (system 
7) to obtain compound 23 (15.3 mg, 47.1%). ESI-MS, m/z: 1308 [M+2H]2+, Found 1308. 
Synthesis of Ga-NOTGA(RGD)3 (24). The solution of Ga(NO3)3 (0.1 M, 26 µL, H2O) was 
added to the solution of compound 23 (5 mg, 1.91 µmol, 800 µL, H2O) and then mixed at 70 ˚C. 
After 20 min, sodium acetate (0.1 M, 20 µL) was added to adjust pH 4 and then the mixture was 
stirred for another 1 h at 70 ˚C. The solution was purified by preparative RP-HPLC (system 8) to 
obtain compound 24 (3.85 mg, 75%). ESI-MS, m/z: 895 [M+3H]3+, Found 895. 
Preparation of [67Ga]Ga-(Hdpp)3. The solution of Hdpp (50 µL, 10 mM, saline) was mixed 
with [67Ga]Ga-citrate (50 µL) and heated at 80 ˚C for 30 min. The radiolabeling solution was 
analyzed by TLC (MeOH : water/1 : 1 with or without 10 mM Hdpp), CAE, and RP-HPLC (system 
3). 
Preparation of [67Ga]Ga-(Sal)3TAMEol. [67Ga]Ga-citrate (20 µL) was added to an ethanolic 
solution of compound 7 (0.5 mg, 1.12 µmol, 1.12 mL) and then heated at 80 ˚C for 15 min. The 
radiolabeling solution was analyzed by RP-HPLC (system 4). 
Preparation of [67Ga]Ga-(PTSC-1)2 and [67Ga]Ga-(PTSC-2)2. [67Ga]GaCl3 (5 µL) was mixed 
with 0.1 M ammonium acetate (pH 4.5, 30 µL) and left for 5 min. A 10 µL of this solution was 
mixed with PTSC derivatives (1.1 mM, 90 µL) dissolved in a mixture of EtOH and 0.1 M 
ammonium acetate pH 4.5 (1:8), and the reaction mixture was heated at 80 ˚C for 15 min. RP-
HPLC analysis was conducted with the system 5 or 6.  
Preparation of [67Ga]Ga-(RGD-Sal)3TAMEol. Compound 16 (3.75 × 10-4 M) and 
TAMEol/3HCl (1.07 × 10-4 M) were dissolved in ammonium acetate (1.0 M, pH 8, 30 µL). 
[67Ga]Ga-citrate (74 MBq/mL) was diluted 10 times with ammonium acetate (2.0 M, pH 8) and 
the diluted [67Ga]Ga-citrate (15 µL) was added to the above mixture and incubated at 70 ˚C for 1 
h (final concentration of compound 16: 2.5 × 10-4 M). For SPECT/CT studies, [67Ga]GaCl3 was 
used. [67Ga]GaCl3 was mixed with the ammonium acetate (1.0 M, pH 7) to prepare [67Ga]Ga-
acetate (7.4 MBq/mL). [67Ga]Ga-acetate (15 µL) was added to the above mixture (30 µL) and then 
incubated at 70˚C for 1 h. The radiochemical yield and purity were determined by TLC 
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(ammonium acetate : MeOH/1 : 1) and RP-HPLC (systems 1 or 2). Furthermore, RP-HPLC 
analysis of the labeling solution using UV detector was also performed.  
Preparation of [67Ga]Ga-NOTGA(RGD)3. Compound 23 (2.0 × 10-4 M) was dissolved in 
ammonium acetate (1.0 M, pH 5, 15 µL). [67Ga]Ga-acetate (7.4 MBq/mL) prepared by the above 
described method was added to the solution (15 µL) and then incubated at 25 ˚C for 20 min. The 
radiochemical yield and purity were determined by RP-HPLC (systems 1 or 2). RP-HPLC analysis 
of the labeling solution using UV detector was also performed. 
Cell line. U87MG glioma cell was purchased from the American Type Culture Collection 
(ATCC, Manassas, VA). These cells were cultured according to protocols prescribed by the 
ATCC.  
Binding affinity to integrin αvβ3. This study was performed according to the procedures 
described in our previous studies.17,18 The half-maximal inhibitory concentration (IC50) was 
determined in competition against [125I]I-c(RGDyV).38 Multiscreen DV filter plates (Merck 
Millipore, MA) were seeded with 2 × 105 cells in the binding buffer (20 mM Tris, 150 mM NaCl, 
2 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, 0.1% BSA, pH 7.4), and the mixtures were incubated 
at 37 ˚C with [125I]I-c(RGDyV) in the presence of c(RGDyV),38 RGD-Sal, Ga-(RGD-
Sal)3TAMEol, NOTGA(RGD)3 or Ga-NOTGA(RGD)3. The total incubation volume was adjusted 
to 200 µL. After incubation for 1 h at 37 ˚C, the plates were filtered and washed twice with 200 
µL of the ice-cold binding buffer. The polyvinylidene fluoride filters were collected and the 
radioactivity was determined using an autowell γ-counter. The IC50 values were calculated by 
fitting the data by nonlinear regression using GraphPad Prism (GraphPad Software, Inc., San 
Diego, CA). All the binding experiments were carried out with quadruplet samples. 
Determination of Log D7.4 values. [67Ga]Ga-(RGD-Sal)3TAMEol and [67Ga]Ga-
NOTGA(RGD)3 were purified by RP-HPLC (system 1), and the eluents of the two compounds 
were evaporated in vacuo. Then, the residues were dissolved in 25 mM phosphate buffer (pH 7.4) 
to prepare 3.7 MBq/mL of sample solutions. Ten µL (37 kBq) of each sample solution was added 
to an equal volume mixture (3 mL : 3 mL) of n-octanol and 25 mM phosphate buffer (pH 7.4) 
preincubated for 24 h to reach equilibrium. The mixtures were vortexed for 1 min, followed by 
being left to stand for 1 min. This procedure was repeated 3 times. The mixtures were then 
centrifuged at 2000 rpm for 10 min. The samples for both n-octanol and aqueous layers were taken 
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and counted in an auto well γ-counter. The log D7.4 values were reported as mean ± SD of 3 
experiments. 
Stability study. 67Ga-labeled complexes were purified by RP-HPLC to remove unlabeled 
ligands. The radioactive peak was collected and the solvent was removed in vacuo. The residue 
was reconstituted in bicarbonate buffer (0.1 M, pH 7.4). To 200 µL of this solution (74 MBq), a 
solution of apo-transferrin (2 mg/mL, 300 µL, 0.1 M carbonate or phosphate buffer pH 7.4) was 
added and incubated at 37 ˚C. Aliquots of samples were collected after being incubated for 1, 3 
and 6 h, and the radioactivity was analyzed by TLC (ammonium acetate : MeOH/1 : 1). 
Animal model. Animal studies were conducted in accordance with the institutional guidelines 
approved by the Chiba University Animal Care Committee. Five-week-old male BALB/c nu/nu 
mice (body weight: ca. 22 g, Japan SLC, Inc., Hamamatsu, Japan) were xenografted by 
subcutaneous injection of U87MG human glioblastoma cells (5 × 106 cells/50 µL of culture 
medium) into their right hind legs. The mice were subjected to biodistribution and SPECT/CT 
imaging studies when the tumor weight reached 0.1−0.5 g (ca. 3-4 weeks after xenograft). 
Biodistribution studies. 100 μL (11 kBq) of [67Ga]Ga-(RGD-Sal)3TAMEol, ([RGD-Sal] = 10 
nmol) was administered to 6-week-old ddY male mice via the tail vein. The animals were 
sacrificed at 10 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours after administration, the blood 
and the tissues of interest were excised, the weight and radioactivity of each tissue were measured. 
Radioactivity of urine and feces by 6 hours excretion was also measured. 
Male nude mice bearing U87MG tumor xenografts were injected via the tail vein with 100 µL 
(11.1 kBq) of [67Ga]Ga-(RGD-Sal)3TAMEol in the presence of RGD-Sal (10 nmol) as the trivalent 
“1 to 3” design. For comparison, [67Ga]Ga-NOTGA(RGD)3 in the presence of NOTGA(RGD)3 (1 
or 10 nmol) was administered to the mice. Moreover, RP-HPLC-purified [67Ga]Ga-(RGD-
Sal)3TAMEol or [67Ga]Ga-NOTGA(RGD)3 were also evaluated using similar methods. The 
animals were sacrificed and dissected at 1 h after administration. The tissues of interest were 
excised and weighed, and the radioactivity was determined with an auto-well γ-counter. The results 
are presented as the percentage injected dose per gram (%ID/g) or percentage injected dose per 
tissues (%ID). Values were expressed as mean ± SD for a group of 4-5 mice. 
Urine analysis. Six hours after the injection of [67Ga]Ga-(RGD-Sal)3TAMEol (74 kBq) into 6-
week-old ddy-mice,47 urine samples were collected. For RP-HPLC analysis of the urine sample, 
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200 µL of acetonitrile was added to 200 µL of urine to precipitate the proteins. The supernatants 
were filtered through a polycarbonate membrane (0.45 µm) before being analyzed by RP-HPLC 
(system 2). 
Small animal SPECT/CT imaging studies. SPECT images were taken 45 min after 
administration of [67Ga]Ga-(RGD-Sal)3TAMEol (100 µL, 1.8 MBq, [RGD-Sal] = 10 nmol) or 
[67Ga]Ga-NOTGA(RGD)3 (100 μL, 2.2 MBq, [NOTGA(RGD)3] = 10 nmol) to male BALB/c 
nu/nu mice bearing U87MG xenografts from the tail vein. CT scans were performed before SPECT 
scans for anatomic reference. The mice were anaesthetized with 1−1.5% (v/v) isoflurane (DS 
Pharma Animal Health, Osaka, Japan) and positioned on the animal bed where anesthesia was 
continuously delivered via a nose cone system. SPECT imaging and X-ray CT imaging were 
performed with a small animal SPECT/CT system (Triumph LabSPECT4/CT, TriFoil Imaging 
Inc., Chatsworth, CA) equipped with a five pinhole (1.0 mm) collimator. Data acquisition was 
performed for 34 min at 120 s per projection with stepwise rotation of 16 projections over 360˚. 
All SPECT data were reconstructed by a 3D-ordered subset expectation maximization (3D-OSEM) 
algorithm method with 2 subset and 5 iterations in FLEX-RECON software (TriFoil Imaging Inc.). 
Statistical analysis. Data are expressed as the means ± SD where appropriate. Results were 
statistically analyzed using the unpaired Student’s t-test or Tukey’s multiple-comparison test. 
Differences were considered statistically significant when p was <0.05. 
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